Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a significant advancement, HMA lead to responses in less than half of patients and for those that respond most will relapse. As such, there is a crucial need to improve frontline therapy approaches. One promising strategy involves combining azacitidine or decitabine with investigational or existing therapies with the goal of achieving synergistic activity and better patient outcomes. The purpose of this paper is to critically review the efficacy and safety of reported HMA-based combination regimens in patients with higher-risk MDS.
['Ball|Brian|B|', 'Zeidan|Amer|A|', 'Gore|Steven D|SD|', 'Prebet|Thomas|T|']
D000074322:Antineoplastic Agents, Immunological D000971:Antineoplastic Combined Chemotherapy Protocols D002986:Clinical Trials as Topic D019175:DNA Methylation D056572:Histone Deacetylase Inhibitors D006801:Humans D000077269:Lenalidomide D058990:Molecular Targeted Therapy D009190:Myelodysplastic Syndromes D047428:Protein Kinase Inhibitors D013792:Thalidomide D016896:Treatment Outcome
hypomethylating agent MDS AML DNA methyltransferase inhibitor combination therapy epigenetic